PRCA
MCID: PRR002
MIFTS: 52

Pure Red-Cell Aplasia (PRCA)

Categories: Blood diseases, Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Pure Red-Cell Aplasia

MalaCards integrated aliases for Pure Red-Cell Aplasia:

Name: Pure Red-Cell Aplasia 12 15 73
Pure Red Cell Aplasia 12 76 53
Primary Red Cell Aplasia 12
Red-Cell Aplasia, Pure 44
Red-Cell Aplasia Pure 55
Red Cell Hypoplasia 12
Prca 53

Classifications:



External Ids:

Disease Ontology 12 DOID:1340
MeSH 44 D012010
NCIt 50 C34974
SNOMED-CT 68 50715003
UMLS 73 C0034902

Summaries for Pure Red-Cell Aplasia

NIH Rare Diseases : 53 Pure red cell aplasia (PRCA) is a rare condition that affects the bone marrow. Bone marrow contains stem cells which develop into the red blood cells that carry oxygen through the body, the white blood cells that fight infections, and the platelets that help with blood clotting. In people with PRCA, the bone marrow makes a reduced number of red blood cells (called anemia). As a result, affected people may experience fatigue, lethargy, and pale skin. PRCA has many different causes. A rare congenital form of PRCA, called Diamond Blackfan syndrome, is an inherited condition that is also associated with other physical abnormalities. PRCA can also be due to certain medications, infections, pregnancy, renal failure, and conditions such as thymomas, autoimmune disease (such as systemic lupus erythematosus), cancers of the blood, and solid tumors. In many cases, the cause of the condition is unknown (idiopathic). The treatment of PRCA aims to address the underlying cause of the condition and relieve the associated signs and symptoms.

MalaCards based summary : Pure Red-Cell Aplasia, also known as pure red cell aplasia, is related to large granular lymphocyte leukemia and chronic graft versus host disease. An important gene associated with Pure Red-Cell Aplasia is EPO (Erythropoietin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PI3K-Akt signaling pathway. The drugs Iron and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Pure red cell aplasia (PRCA) or erythroblastopenia refers to a type of anemia affecting the precursors... more...

Related Diseases for Pure Red-Cell Aplasia

Diseases in the Pure Red-Cell Aplasia family:

Acquired Pure Red Cell Aplasia

Diseases related to Pure Red-Cell Aplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 272)
# Related Disease Score Top Affiliating Genes
1 large granular lymphocyte leukemia 31.1 IL2RA STAT3
2 chronic graft versus host disease 30.6 ALB IL2RA
3 hematopoietic stem cell transplantation 30.6 HLA-A HLA-B IL2
4 chronic kidney failure 30.6 ALB EPO TF
5 celiac disease 1 30.4 ALB HLA-A IL2
6 rheumatoid arthritis 30.3 HLA-B HLA-DRB1 IL2 IL2RA
7 myeloma, multiple 30.3 ALB EPO IL2 STAT3
8 t-cell large granular lymphocyte leukemia 30.2 IL2 STAT3
9 marasmus 30.2 ALB TF
10 kwashiorkor 30.2 ALB TF
11 graft-versus-host disease 30.2 HLA-A HLA-B HLA-DRB1 IL2
12 hemosiderosis 30.0 EPO TF
13 deficiency anemia 30.0 ALB EPO TF
14 acute disseminated encephalomyelitis 30.0 HLA-B HLA-DRB1
15 sclerosing cholangitis 30.0 ALB HLA-B HLA-DRB1
16 cholangitis 30.0 ALB HLA-B HLA-DRB1
17 autoimmune disease 29.4 HLA-B HLA-DRB1 IL2 IL2RA STAT3
18 aplastic anemia 29.3 ALB EPO HLA-A HLA-B HLA-DRB1 IL2
19 acquired immunodeficiency syndrome 29.1 ALB EPO HLA-B IL2 IL2RA
20 acquired pure red cell aplasia 13.0
21 transient erythroblastopenia of childhood 12.3
22 diamond-blackfan anemia 12.1
23 diamond-blackfan anemia 1 11.5
24 thymoma 11.0
25 leukemia 10.9
26 lymphocytic leukemia 10.8
27 leukemia, chronic lymphocytic 2 10.8
28 leukemia, chronic lymphocytic 10.8
29 hepatitis 10.8
30 leukemia, b-cell, chronic 10.8
31 lupus erythematosus 10.8
32 systemic lupus erythematosus 10.8
33 lymphoma 10.7
34 hemolytic anemia 10.7
35 anemia, autoimmune hemolytic 10.7
36 myasthenia gravis 10.6
37 myasthenia gravis congenital 10.6
38 arthritis 10.6
39 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.5
40 thrombocytopenia 10.5
41 myelodysplastic syndrome 10.5
42 hepatitis c 10.5
43 hepatitis a 10.5
44 b-cell lymphomas 10.4
45 viral infectious disease 10.4
46 kidney disease 10.4
47 acquired amegakaryocytic thrombocytopenia 10.4
48 good syndrome 10.3
49 adult-onset still's disease 10.3
50 viral hepatitis 10.3

Graphical network of the top 20 diseases related to Pure Red-Cell Aplasia:



Diseases related to Pure Red-Cell Aplasia

Symptoms & Phenotypes for Pure Red-Cell Aplasia

GenomeRNAi Phenotypes related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.74 HLA-A HLA-B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.74 RPS17
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.74 HLA-A HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.74 HLA-A HLA-B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.74 HLA-A HLA-B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.74 RPS17
7 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.74 RPS17
8 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.74 HLA-A HLA-B
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.74 HLA-A HLA-B
10 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.74 RPS17
11 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.74 HLA-A HLA-B
12 Increased shRNA abundance (Z-score > 2) GR00366-A-37 9.74 RPS17
13 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.74 RPS17
14 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.74 HLA-A HLA-B RPS17
15 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.74 HLA-A HLA-B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.74 RPS17

Drugs & Therapeutics for Pure Red-Cell Aplasia

Drugs for Pure Red-Cell Aplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 22916-47-8 4189
3
Darbepoetin alfa Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 11096-26-7, 209810-58-2
4
Deferasirox Approved, Investigational Phase 4,Phase 3,Phase 2 201530-41-8 5493381
5
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
6
Everolimus Approved Phase 4,Phase 2 159351-69-6 6442177
7
Sirolimus Approved, Investigational Phase 4,Phase 2 53123-88-9 46835353 6436030 5284616
8 Antibodies Phase 4,Phase 3,Phase 2
9 Hematinics Phase 4,Phase 3,Phase 2,Not Applicable
10 Immunoglobulins Phase 4,Phase 3,Phase 2
11 Epoetin alfa Phase 4,Phase 3,Phase 2 113427-24-0
12 Liver Extracts Phase 4,Phase 1,Phase 2
13 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
16 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Antifungal Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Trace Elements Phase 4,Phase 3
19 Chelating Agents Phase 4,Phase 3,Phase 2
20 Iron Chelating Agents Phase 4,Phase 3,Phase 2
21 Micronutrients Phase 4,Phase 3
22 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Not Applicable
23 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 6055-19-2, 50-18-0 2907
25
Lenograstim Approved, Investigational Phase 2, Phase 3,Not Applicable 135968-09-1
26
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 83-43-2 6741
27
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-24-8 5755
28
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Not Applicable 302-25-0
29
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Not Applicable 2921-57-5
30
Benzocaine Approved, Investigational Phase 3,Phase 2 94-09-7, 1994-09-7 2337
31 tannic acid Approved Phase 3,Phase 2
32 Orange Approved Phase 3
33
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
34
Vidarabine Approved, Investigational Phase 2, Phase 3,Phase 3 24356-66-9 32326 21704
35
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
36
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1 216503-57-0
37
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
38
Prednisolone hemisuccinate Experimental Phase 3,Phase 2,Not Applicable 2920-86-7
39 Alkylating Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
40 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
41 Antilymphocyte Serum Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
42 Antirheumatic Agents Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
43 Methylprednisolone acetate Phase 3,Phase 2,Not Applicable
44 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
45 Cyclosporins Phase 3,Phase 2,Phase 1,Not Applicable
46 Autonomic Agents Phase 3,Phase 2,Not Applicable
47 Gastrointestinal Agents Phase 3,Phase 2,Not Applicable
48 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
49 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
50 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Unknown status NCT02648126 Phase 4
2 Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v. Completed NCT00632125 Phase 4 HX575 recombinant human erythropoietin alfa
3 A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) Completed NCT00773513 Phase 4 Darbepoetin Alfa;Epoetin Alfa;Epoetin Beta;methoxy polyethylene glycol-epoetin beta
4 Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload Completed NCT00673608 Phase 4 deferasirox
5 Tacrolimus Treatment for Refractory PRCA Recruiting NCT03540472 Phase 4 tacrolimus
6 Sirolimus Treatment for Refractory PRCA Recruiting NCT03364764 Phase 4 Sirolimus
7 Efficacy and Safety Study of GerEPO Completed NCT00229099 Phase 3 GerEPO
8 Iron Sucrose in Stage 3/4 Kidney Disease Completed NCT00202345 Phase 3 Iron sucrose
9 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Completed NCT00235391 Phase 3 Deferasirox
10 Stem Cell Transplant for Bone Marrow Failure Syndromes Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
11 Stem Cell Transplant for Hemoglobinopathy Active, not recruiting NCT00176852 Phase 2, Phase 3 Busulfan, Fludarabine, ATG, TLI;Busulfan, Cyclophosphamide, ATG, GCSF;Campath, Fludarabine, Cyclophosphamide
12 Erythropoietin in Management of Neonatal Hypoxic Ischemic Encephalopathy Not yet recruiting NCT03163589 Phase 3 Erythropoietin;normal saline
13 Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment Terminated NCT01288131 Phase 3 Cyclosporine combine with mycophenolate mofetil;Cyclophosphamide + pred
14 A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer Terminated NCT00246597 Phase 3 epoetin alfa
15 Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Terminated NCT00858364 Phase 3 Darbepoetin alfa;Placebo
16 Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease Terminated NCT00436748 Phase 3 Darbepoetin Alfa;Placebo
17 L-leucine in Diamond Blackfan Anemia Patients Unknown status NCT02386267 Phase 2 L-leucine
18 Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia Completed NCT00229619 Phase 2 Rituximab
19 Efficacy and Safety of Peginesatide in the Treatment of Anemia in Patients With Chronic Kidney Disease Completed NCT00314795 Phase 2 peginesatide
20 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
21 A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity Completed NCT01044186 Phase 2 ICL670
22 Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia Completed NCT00011505 Phase 2 G-CSF
23 Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs Completed NCT00957931 Phase 2
24 Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission Completed NCT00305708 Phase 1, Phase 2 busulfan;fludarabine phosphate
25 Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders Completed NCT00301834 Phase 2 busulfan;cyclosporine;fludarabine phosphate;methotrexate;methylprednisolone
26 Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias Completed NCT00061763 Phase 2 Deferasirox
27 Medical Treatment for Diamond Blackfan Anemia Completed NCT00001749 Phase 2 Antithymocyte globulin;Cyclosporine
28 Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor Recruiting NCT03214354 Phase 2 Alemtuzumab;Sirolimus
29 Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure Recruiting NCT02105766 Phase 2 Alemtuzumab;Sirolimus;Cyclophosphamide;Pentostatin
30 Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan Anemia Recruiting NCT01464164 Phase 1, Phase 2 Sotatercept;Sotatercept with prednisone boost
31 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
32 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells Recruiting NCT01174108 Phase 2
33 T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease and Thalassemia Recruiting NCT03653338 Phase 1, Phase 2 Hydroxyurea;Rituximab;Alemtuzumab;Fludarabine;Thiotepa
34 Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
35 Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia Active, not recruiting NCT01362595 Phase 1, Phase 2 leucine
36 Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant Active, not recruiting NCT02065869 Phase 1, Phase 2 rimiducid
37 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
38 Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study Enrolling by invitation NCT03733249 Phase 1, Phase 2 Rimiducid
39 Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies Suspended NCT01419704 Phase 1, Phase 2
40 A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure Terminated NCT00001962 Phase 2 Daclizumab
41 The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias Terminated NCT00472433 Phase 2 Alemtuzumab
42 A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002) Terminated NCT00968617 Phase 2 MK2578;MK2578;MK2578;Comparator: darbepoetin alfa
43 A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12) Terminated NCT00924781 Phase 2 MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline;MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline;MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
44 Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells Terminated NCT02512679 Phase 2 Cyclophosphamide Dose Level 1;Cyclophosphamide Dose Level 2;Cyclophosphamide Dose Level 3;Cyclophosphamide Dose Level 4
45 BMT Abatacept for Non-Malignant Diseases Active, not recruiting NCT01917708 Phase 1 Abatacept
46 Human Placental-Derived Stem Cell Transplantation Active, not recruiting NCT01586455 Phase 1 Human Placental Derived Stem Cell
47 Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia Terminated NCT01034592 Phase 1 Lenalidomide
48 Identifying Characteristics of Bone Marrow Failure Syndromes Unknown status NCT00315419
49 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 Not Applicable anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
50 Multi-Center Study of Iron Overload: Survey Study (MCSIO) Unknown status NCT01913548

Search NIH Clinical Center for Pure Red-Cell Aplasia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: red-cell aplasia, pure

Genetic Tests for Pure Red-Cell Aplasia

Anatomical Context for Pure Red-Cell Aplasia

MalaCards organs/tissues related to Pure Red-Cell Aplasia:

41
Bone, Bone Marrow, T Cells, Kidney, Skin, B Cells, Liver

Publications for Pure Red-Cell Aplasia

Articles related to Pure Red-Cell Aplasia:

(show top 50) (show all 948)
# Title Authors Year
1
Recovery of Pure Red Cell Aplasia Following Hematopoietic Stem Cell Transplantation Associated with IL-6 Elevation Caused by Odontogenic Infection. ( 29877260 )
2018
2
Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation. ( 29079126 )
2018
3
The clinical characteristics and therapy response of patients with acquired pure red cell aplasia. ( 29754581 )
2018
4
Pure red cell aplasia with t-cell large granular lymphocytic leukemia. ( 29921385 )
2018
5
Acquired Amegakaryocytic Thrombocytopenia and Pure Red Cell Aplasia in Thymoma. ( 29713553 )
2018
6
Sirolimus for the treatment of multi-resistant pure red cell aplasia. ( 29741762 )
2018
7
Del(5q) myelodysplastic syndrome combined with pure red cell aplasia. ( 29963514 )
2018
8
Pure red cell aplasia and HIV infection: what to suspect? ( 29680800 )
2018
9
Rational management approach to pure red cell aplasia. ( 29217782 )
2018
10
Identification of mutations in patients with acquired pure red cell aplasia. ( 29767669 )
2018
11
An Unexpected Cause of Acute Enteritis in a Patient with Pure Red Cell Aplasia Parvovirus B19-Associated Acute Enteritis. ( 29610498 )
2018
12
Acquired Pure Red Cell Aplasia and Acquired Amegakaryocytic Thrombocytopenia Associated With Clonal Expansion of T-Cell Large Granular Lymphocytes in a Patient With Lipopolysaccharide-responsive Beige-like Anchor (LRBA) Protein Deficiency. ( 30188351 )
2018
13
Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center. ( 29589280 )
2018
14
Successful treatment of refractory/relapsed acquired pure red cell aplasia with sirolimus. ( 29982851 )
2018
15
Aggressive Systemic Mastocytosis in Association with Pure Red Cell Aplasia. ( 30069418 )
2018
16
Progressive peripheral CD8+ T lymphocytosis complicated by pure red cell aplasia following immunosuppressive therapy for thymoma-associated myasthenia gravis. ( 30056258 )
2018
17
Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide. ( 29998058 )
2018
18
Pure red cell aplasia caused by azathioprine: case report and review of the literature. ( 30156166 )
2018
19
Pure red cell aplasia and anti-erythropoietin antibodies in patients on hemodialysis: a report of two cases and a literature review. ( 30160771 )
2018
20
Pure red cell aplasia associated with thymoma: a report of a single-center experience. ( 30233881 )
2018
21
Linezolid-induced pure red cell aplasia: a case report and literature review. ( 30270705 )
2018
22
Isoniazid-induced pure red cell aplasia. ( 30297494 )
2018
23
Frequent STAT3 mutations in CD8+ T cells from patients with pure red cell aplasia. ( 30337298 )
2018
24
No post-transplant pure red cell aplasia development in 106 major ABO incompatible cord blood transplantation. ( 30401968 )
2018
25
Pure Red Cell Aplasia Associated with Thymolipoma: Complete Anaemia Resolution following Thymectomy. ( 30402302 )
2018
26
Successful treatment of pure red cell aplasia because of ABO major mismatched stem cell transplant. ( 28543448 )
2017
27
Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients. ( 28042550 )
2017
28
Polyparaneoplastic Manifestations of Malignant Thymoma: A Unique Case of Myasthenia, Autoimmune Hepatitis, Pure Red Cell Aplasia, and Keratoconjunctivitis Sicca. ( 28744421 )
2017
29
Successful treatment of tacrolimus-related pure red cell aplasia and autoimmune hemolytic anemia with rituximab in a pediatric cardiac transplant patient. ( 28598573 )
2017
30
T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia. ( 29296951 )
2017
31
Haemolysis, pure red cell aplasia and red cell antibody formation associated with major and bidirectional ABO incompatible haematopoietic stem cell transplantation. ( 28488966 )
2017
32
A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma. ( 28872489 )
2017
33
Use of Nandrolone Decanoate in Treatment of Pure Red Cell Aplasia Secondary to Diclofenac Administration: A Case Report. ( 28750791 )
2017
34
Isoniazid-induced Pure Red Cell Aplasia in a Patient with Sarcoidosis: A Patient Summary and Review of the Literature. ( 28924112 )
2017
35
Trend and treatment patterns of aplastic anemia in Korea, pure red cell aplasia and myelodysplastic syndrome in Korea: a nation-wide analysis. ( 28664500 )
2017
36
Cyclosporin A Reversed Chemoresistance of a Patient with Pure Red Cell Aplasia Secondary to Thymoma. ( 28739760 )
2017
37
Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib. ( 27756158 )
2017
38
Refractory Pure Red Cell Aplasia Manifesting as Deficiency of Adenosine Deaminase 2. ( 28230570 )
2017
39
Pure red cell aplasia and myasthenia gravis: a patient having both autoimmune conditions in the absence of thymoma. ( 28893803 )
2017
40
Pure Red Cell Aplasia Due to Parvovirus B19: Erythropoietin-Resistant Anemia in a Pediatric Kidney Recipient. ( 28387173 )
2017
41
Pure Red Cell Aplasia Associated with Monoclonal Gammopathy of Undetermined Significance and Literature Review. ( 28182355 )
2017
42
Pure Red Cell Aplasia Associated with Good Syndrome. ( 28382272 )
2017
43
Epoetin-β induced pure red cell aplasia: an unintended consequence. ( 27932518 )
2017
44
Linezolid Induced Twice Pure Red Cell Aplasia in a Patient with Central Nervous System Infection after Allogeneic Stem Cell Transplantation. ( 27642338 )
2016
45
Successful treatment of a hemodialyzed patient with pure red cell aplasia associated with epoetin beta pegol therapy with cyclosporine. ( 28509169 )
2016
46
Primary acquired chronic pure red cell aplasia refractory to standard treatments: remission with rituximab. ( 27382560 )
2016
47
TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib. ( 27843612 )
2016
48
Post renal transplant pure red cell aplasia-is tacrolimus a culprit? ( 27478605 )
2016
49
Monoclonal gammopathy-associated pure red cell aplasia. ( 26999424 )
2016
50
Unusual co-occurrence of Evans syndrome and pure red cell aplasia in elderly patient with prostate cancer. ( 27465154 )
2016

Variations for Pure Red-Cell Aplasia

Expression for Pure Red-Cell Aplasia

Search GEO for disease gene expression data for Pure Red-Cell Aplasia.

Pathways for Pure Red-Cell Aplasia

Pathways related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.11 HLA-A HLA-B HLA-DRB1 IL2 IL2RA STAT3
2
Show member pathways
12.75 EPO HLA-A HLA-B IL2 IL2RA
3 12.63 EPO IL2 IL2RA STAT3
4
Show member pathways
12.54 HLA-A HLA-B HLA-DRB1 IL2 IL2RA TRB
5
Show member pathways
12.43 HLA-DRB1 IL2 IL2RA TRB
6
Show member pathways
12.34 HLA-DRB1 IL2 IL2RA STAT3 TRB
7
Show member pathways
12.32 HLA-A HLA-B HLA-DRB1 IL2 IL2RA STAT3
8
Show member pathways
12.16 EPO IL2 IL2RA STAT3
9 12.11 HLA-A HLA-B STAT3
10
Show member pathways
12.07 HLA-A HLA-B IL2 IL2RA
11 12.06 HLA-A HLA-B HLA-DRB1 STAT3
12 12.06 HLA-A HLA-B HLA-DRB1 IL2 IL2RA
13 11.96 HLA-A HLA-B HLA-DRB1
14 11.93 HLA-A HLA-B HLA-DRB1
15
Show member pathways
11.89 IL2 IL2RA STAT3
16
Show member pathways
11.85 IL2 IL2RA STAT3
17 11.81 EPO IL2 IL2RA
18 11.72 EPO STAT3 TF
19 11.7 EPO HLA-DRB1 IL2RA
20 11.61 EPO IL2 IL2RA STAT3
21
Show member pathways
11.44 HLA-A IL2 IL2RA
22 11.16 IL2 IL2RA
23
Show member pathways
11.15 HLA-A HLA-DRB1 IL2 IL2RA STAT3 TRB
24 11.12 IL2 TRB
25
Show member pathways
11.09 IL2RA STAT3
26 11.07 HLA-DRB1 IL2 TRB
27 11.02 HLA-A HLA-B
28 10.7 HLA-DRB1 IL2 IL2RA STAT3

GO Terms for Pure Red-Cell Aplasia

Cellular components related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ER to Golgi transport vesicle membrane GO:0012507 9.33 HLA-A HLA-B HLA-DRB1
2 MHC class I protein complex GO:0042612 9.26 HLA-A HLA-B
3 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-A HLA-B HLA-DRB1
4 cell surface GO:0009986 9.1 EPO HLA-A HLA-B HLA-DRB1 IL2RA TF

Biological processes related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 ALB EPO IL2 STAT3
2 immune system process GO:0002376 9.77 HLA-A HLA-B HLA-DRB1 IL2 IL2RA
3 immune response GO:0006955 9.65 HLA-A HLA-B HLA-DRB1 IL2 IL2RA
4 interferon-gamma-mediated signaling pathway GO:0060333 9.63 HLA-A HLA-B HLA-DRB1
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 EPO IL2 STAT3
6 acute-phase response GO:0006953 9.59 EPO STAT3
7 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.58 HLA-A HLA-B
8 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.57 HLA-A HLA-B
9 positive regulation of T cell mediated cytotoxicity GO:0001916 9.56 HLA-A HLA-B
10 positive regulation of T cell differentiation GO:0045582 9.55 IL2 IL2RA
11 regulation of regulatory T cell differentiation GO:0045589 9.54 IL2 IL2RA
12 inflammatory response to antigenic stimulus GO:0002437 9.52 HLA-DRB1 IL2RA
13 interleukin-2-mediated signaling pathway GO:0038110 9.51 IL2 IL2RA
14 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.49 HLA-A HLA-B
15 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.48 HLA-A HLA-B
16 negative regulation of lymphocyte proliferation GO:0050672 9.4 IL2 IL2RA
17 antigen processing and presentation GO:0019882 9.33 HLA-A HLA-B HLA-DRB1
18 protection from natural killer cell mediated cytotoxicity GO:0042270 9.32 HLA-A HLA-B
19 regulation of T cell homeostatic proliferation GO:0046013 8.96 IL2 IL2RA
20 positive regulation of activated T cell proliferation GO:0042104 8.8 EPO IL2 IL2RA

Molecular functions related to Pure Red-Cell Aplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.8 HLA-A HLA-B HLA-DRB1

Sources for Pure Red-Cell Aplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....